Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PLUR vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–2 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: PLUR 1 – 4 OVID (1 Tie) Matrix Metrics: PLUR 2 – 7 OVID

As of Nov 17, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.19 (1.8x Forward P/E, -4693.7% operating margin).

  • Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. PLUR 28.8/100 SELL) and 1.06β · 99% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUR vs OVID
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.19
-8.54% 1D
Market Cap $479.4M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.06β · 99% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 29.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $2.51 · SMA50: $2.49

6-Pillar Scorecard Institutional Category Breakdown (PLUR 1 – 4 OVID)

Columns: Metric · PLUR · OVID
1. Valuation Multiples OVID
Forward P/E 3.6x 1.8x
Trailing P/E 3.6x 1.8x
PEG Ratio N/M N/M
EV / Revenue 44.6x N/M
2. Growth & Scale PLUR
Revenue Growth (YoY) -15.8% -88.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.0M $1.5M
Market Cap $15.1M $479.4M
3. Profitability & Quality OVID
Gross Margin 44.6% 100.0%
Operating Margin -2454.5% -4693.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1022.0% -35.4%
4. Balance Sheet & Cash Flow OVID
Cash Generation (TTM) -$22M -$58M
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Debt $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OVID
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 131.0% (30th %ile)
Put/Call OI Skew N/A 0.06x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUR (2) vs OVID (7)
Institutional Metric PLUR OVID Criterion Row Edge
Market Capitalization
Scale
$15.1M $479.4M Larger Scale OVID
Trailing P/E Ratio
Valuation
3.6x 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
3.6x 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
-15.8% -88.3% Higher Growth PLUR
Operating Margin (TTM)
Profitability
-2454.5% -4693.7% Higher Margin PLUR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1022.0% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
2% ($1–$5) 53% ($1–$3) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
0.80β · 102% Vol 1.06β · 99% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
28.8 / 100 (SELL) 52.3 / 100 (HOLD) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$1.0M $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 44.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($30M Net Debt) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +9.94 pp
PLUR: +11.09% · OVID: +1.15%
3M Horizon OVID +21.25 pp
PLUR: -46.34% · OVID: -25.09%
6M Horizon OVID +53.98 pp
PLUR: -62.52% · OVID: -8.54%
1Y Horizon OVID +143.73 pp
PLUR: -75.53% · OVID: +68.2%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PLUR Revenue OVID Revenue PLUR Op. Margin OVID Op. Margin Margin Leader
FY2019 $0M N/A -65800.0% N/A PLUR
FY2020 $0M $10M -128156.5% -645.4% OVID
FY2021 N/A $210M N/A 59.6% OVID
FY2022 $0M $0M -17774.8% -3696.4% OVID
FY2023 $0M $0M -9493.4% -15122.7% PLUR
FY2024 $0M $0M -6796.9% -10933.7% PLUR
FY2025 $0M $10M -1659.9% -585.2% OVID
FY2026 $0M N/A -2454.5% N/A PLUR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID CONSOLIDATION
151d in phase · OBV DISTRIBUTION
Current IV 131.0%
IV Percentile 30th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $479.4M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLUR vs OVID Key Questions & Quantitative Answers

As of Nov 17, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.19 (1.8x Forward P/E, -4693.7% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. PLUR 28.8/100 SELL) and 1.06β · 99% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLUR leads the Growth & Scale pillar: PLUR posts -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PLUR cumulative revenue shifted N/A while OVID shifted +0.0%. In operating R&D and SG&A reinvestment, PLUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUR (-1022.0% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk). By comparison, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 99% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.